DRX-065, deuterium-stabilized R-pioglitazone, is in Phase 1 for adrenomyeloneuropathy (AMN) and nonalcoholic steatohepatitis (NASH).

  • Pioglitazone (pio) is the most extensively studied drug for NASH. It has better efficacy than several late stage drug candidates, and is the only drug recommended off-label by AASLD and EASL. For AMN, pio has demonstrated stabilization and reversal of disease in rodent models. Interest in pio for NASH and AMN, however, has been limited due to the PPAR-gamma agonism side effects of weight gain, edema, and risk of bone fractures.
  • In preclinical models, DRX-065 is a mitochondrial function modulator responsible for the anti-inflammatory activity and NASH efficacy of pio without the PPAR-gamma activity and related side effects that are due to S-pio.
  • From our Phase 1 study, DRX-065 provides selective exposure to R-pio and is predicted to have efficacy equivalent to 45 mg pio without the PPAR-gamma related side effects.

DRX-164, deuterium-stabilized S-avadomide, is in preclinical development for hematological malignancies and solid tumors.

  • Avadomide (CC-122) is in clinical development at Celgene as the first in a new series of cereblon E3 ligase modulators (CELMoDsĀ®). It is more potent than lenalidomide and is being studied in clinical trials without dexamethasone.
  • In preclinical models, DRX-164 exhibits the cereblon binding, anti-inflammatory, and anti-tumorigenic activity of CC-122 while the R-enantiomer exhibits potential tumor-promoting effects in a xenograft model of multiple myeloma.

  • For additional information, please contact:
    • DeuteRx, LLC
    • 300 Brickstone Square, Suite 201
    • Andover MA 01810
    • Phone: 978-662-5287
      Email: info@deuterx.com
Compelling Commercial Strategy
& Large Portfolio of
Product Opportunities